Co-expression of CDX2 and MUC2 in gastric carcinomas: Correlations with clinico-pathological parameters and prognosis

Table 1 Correlation of CDX2 and MUC2 expression with clinico-pathological parameters and classifications.

Parameter	n	CDX2 positive cases (%)	MUC2 positive cases (%)
Age (yr)
≤60 yr	87	48 (55.2)	14 (16.1)
＞60 yr	103	61 (59.2)	27 (26.2)
P		0.57	0.09
Gender
Female	90	57 (63.3)	21 (23.3)
Male	100	52 (52)	20 (20)
P		0.11	0.58
WHO classification
Mucinous	4	3 (75)	4 (100)
Signet-ring cell	85	49 (57.6)	13 (15.3)
Tubular/papillary	80	47 (58.8)	20 (25)
Undifferentiated	21	10 (47.6)	4 (19)
P		0.71	0.0007
Lauren classification
Diffuse	105	61 (58.1)	19 (18.1)
Intestinal	70	40 (57.1)	18 (25.7)
Unclassified/mixed	15	8 (53.3)	4 (26.7)
P		0.94	0.43
Goseki classification
Type I	54	30 (55.6)	14 (25.9)
Type II	22	16 (72.7)	6 (27.3)
Type III	20	9 (45)	3 (15)
Type IV	94	54 (57.4)	18 (19.1)
P		0.33	0.60
pTNM stages
I	53	29 (54.7)	7 (13.2)
II	58	41 (70.7)	18 (31)
III	54	27 (50)	10 (18.5)
IV	25	12 (48)	6 (24)
P		0.09	0.13
pT stages
pT1	33	16 (48.5)	4 (12.1)
pT2	112	69 (61.6)	28 (25)
pT3	32	18 (56.3)	6 (18.8)
pT4	13	6 (45.2)	3 (23.1)
P		0.46	0.44
pN stages
pN0	52	31 (59.6)	8 (15.4)
pN1	76	48 (63.2)	21 (27.6)
pN2	52	25 (48.1)	9 (17.3)
pN3	10	5 (50)	3 (30)
P		0.36	0.28

Table 2 Expression of CDX2 and MUC2 in non-tumorous gastric mucosa, intestinal metaplasia, and carcinomas.

Localization of staining	Score	Gastric mucosa (%)	Intestinal metaplasia (%)	Carcinoma (%)
CDX2	0 1	9 (18.3)	5 (8.6)	81 (42.6)
Nuclear	1	2 (1.9)	3 (5.2)	6 (3.2)
	2	1 (1)	5 (8.6)	9 (4.7)
	3	3 (2.9)	12 (20.7)	8 (4.2)
Supranuclear	1	17 (16.3)	5 (8.6)	14 (7.4)
	2	18 (17.3)	2 (3.4)	18 (9.5)
	3	22 (21.2)	6 (10.3)	31 (16.3)
Cytoplasmic	1	10 (9.6)	0	3 (1.6)
	2	4 (3.8)	0	2 (1.1)
	3	3 (2.9)	0	2 (1.1)
Mixed	1	0	0	2 (1.1)
	2	3 (2.9)	1 (1.7)	2 (1.1)
	3	2 (1.9)	19 (32.8)	12 (6.3)
MUC2	0	97 (93.3)	9 (15.5)	149 (78.4)
Supranuclear	1	5 (4.8)	19 (32.8)	22 (11.6)
	2	2 (1.9)	14 (24.1)	13 (6.8)
	3	0	16 (27.6)	6 (3.2)

Table 3 Correlation of CDX2 expression with clinico-pathological parameters and classifications in intestinal carcinomas according to Laurén.

Parameter	n	CDX2 positive cases (%)
Age (yr)
≤60 yr	26	10 (38.5)
＞60 yr	44	30 (68.2)
P		0.02
Gender
Female	29	21 (72.4)
Male	41	19 (46.3)
P		0.03
pTNM stages
I	21	13 (61.9)
II	23	18 (78.3)
III	17	4 (23.5)
IV	9	5 (55.6)
P		0.01
pN stages
pN0	22	14 (63.6)
pN1	26	18 (69.2)
pN2	20	6 (30)
pN3	2	2 (100)
P		0.02

Table 4 Correlation of CDX2 and MUC2 expression.

	n	CDX2 negative	CDX2 positive
All cases	190	81	109
MUC2 negative	149	72	77
MUC2 positive	41	9	32
P				0.003
Intestinal type (Laurén)	70	30	40
MUC2 negative	52	26	26
MUC2 positive	18	4	14
P				0.04
Diffuse type (Laurén)	105	44	61
MUC2 negative	86	41	45
MUC2 positive	19	3	16
P				0.01
Stage I (pTNM)	53	24	29
MUC2 negative	46	24	22
MUC2 positive	7	0	7
P				0.01

Table 5 Univariate survival analysis with regard to the CDX2 and MUC2 expression.

CDX2 expression	Observations	Uncensored	Censored	Survival (yr)	SD	P (log-rank)
Negative	81	57	24
Q1 (25%)				0.799	0.216
Median				1.884	0.062
Q2 (75%)				0	0
Mean				3.606	0.369
Positive	109	72	37
Q1 (25%)				1.060	0.069
Median				2.968	1.108
Q2 (75%)				11.524	0
Mean				5.184	0.461	0.28
MUC2 expression
Negative	149	100	49
Q1 (25%)				0.942	0.102
Median				2.171	0.368
Q2 (75%)				11.524	0
Mean				4.966	0.394
Positive	41	29	12
Q1 (25%)				1.024	0.361
Median				2.557	1.284
Q2 (75%)				0	0
Mean				2.788	0.315	0.61